Clinical Trial
Study Details
Status
RECRUITING
Study ID #
NCT05635266
Study Start
Primary Completion
Study Completion
Enrollment
20000
Study Type
Observational
Interventions
Specimen sample

The study may require a tissue collection and/or a participant survey for participation. Most tissue collected will come from a blood draw; up to 100mL for the health condition group, 60mL for the exceptive condition group, and up to 180mL for the control group (if determined safe for the participant). Participant surveys may involve participant reported outcomes (PROs) or custom participant surveys.

Primary Outcomes
Measure
Biospecimen & Clinical Data Collection
Description

To collect enough biospecimens and associated clinical data to allow researchers to come to statistically relevant scientific results

Timeframe
10 years
Summary

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.

Conditions
Age-Related Macular Degeneration
Allergies
Alpha-Gal Syndrome
Alzheimer Disease
Amyloidosis
Ankylosing Spondylitis
Arthritis
Alopecia Areata
Asthma
Atopic Dermatitis
Autism
Autoimmune Hepatitis
Behcet's Disease
Beta-Thalassemia
Cancer
Celiac Disease
Kidney Diseases
COPD
Crohn Disease
Cystic Fibrosis
Diabetes
Dravet Syndrome
DMD
Fibromyalgia
Graves Disease
Thyroid Diseases
Hepatitis
Hidradenitis Suppurativa
ITP
Leukemia
ALS
Lupus or SLE
Lymphoma
Multiple Sclerosis
Myasthenia Gravis
Heart Diseases
Parkinson Disease
Pemphigus Vulgaris
Cirrhosis
Psoriasis
Schizophrenia
Scleroderma
Sickle Cell Disease
Stroke
Ulcerative Colitis
Vasculitis
Vitiligo
Study Contact
Name
Carolyn Bidwell
Role
Contact
Phone
855.836.4759
Email
study@sanguinebio.com
Locations
Facility

Sanguine Biosciences
Waltham, MA 02451
United States

Eligibility Criteria

Inclusion Criteria:

* Persons 18 to 85 years of age at the date of informed consent.
* If presenting with a history of a specific condition, the diagnosis is confirmable in the medical record or may be confirmed using other forms of verification including self-reporting.
* Understands the procedures and requirements of the study by providing written informed consent (or verbal assent if a legally authorized representative will sign the ICF), including consent for authorization for protected health information disclosure.

Exclusion Criteria:

* Persons younger than 18 years of age or older than 85 years of age at the date of informed consent.
* Receipt of blood products 30 days before the study blood draw.
* Receipt of an investigational (unapproved) drug 30 days before the study blood draw.
* A confirmable diagnosis of any medical condition that would increase potential phlebotomy risks.
* Has donated a unit of blood within the last 2 months at the date of informed consent.

Eligibility Minimum Age
18 Years
Eligibility Maximum Age
85 Years
Sexes Eligible for Study
ALL
Eligibility Std Ages
Adult
Older Adult
Study Population

Health condition, exceptive condition, and control participants will be recruited by one or any of the following resources, but not limited to:

* Use of online marketing where potential participants receive study information from the Sanguine's website or online participant referral program;
* In the site investigators (or PI's) clinic; and/or
* Through community advocacy programs.
* Participant Referral